Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on developing and commercializing innovative cancer therapies. It specializes in the research of selective inhibitors of nuclear export (SINE) compounds, with its lead product, XPOVIO (selinexor), approved for treating multiple myeloma and certain types of lymphoma. The company generates revenue primarily through product sales, licensing agreements, and collaborations. Founded in 2008, Karyopharm has a history of pioneering advancements in oncology, aiming to address unmet medical needs in cancer treatment.